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ABSTRACT
Background: There has been an increasing interest in monitoring the fractional concentrations of exhaled NO
(FeNO) levels in allergic rhinitis (AR) patients. In the present study, we examined whether the nasal FeNO
measurement might reflect the degree of local allergic inflammation as well as subjective symptoms.
Methods: The FeNO measurement was performed using a handheld electrochemical analyzer (NObreathⓇ)
with a nose adaptor. In the cross-sectional study, 56 patients with perennial AR patients, 18 AR patients with
bronchial asthma (BA), 12 patients with vasomotor rhinitis, and 30 normal subjects were enrolled. For the
follow-up study, 12 seasonal allergic rhinitis (SAR) patients against Japanese cedar and 10 perennial AR pa-
tients who underwent laser surgery were examined.
Results: The AR patients and vasomotor rhinitis patients showed significantly higher oral FeNO levels as
compared with the normal subjects. The nasal FeNO levels were significantly higher in the perennial AR pa-
tients with or without BA than in the normal subjects and vasomotor rhinitis patients. There were positive corre-
lations between the nasal symptom scores and FeNO levels. The SAR patients showed a significant decrease
in the nasal FeNO level after the pollen dispersion season. In addition, the therapeutic effects of laser surgery
in the AR patients accompanied a significant reduction in the nasal FeNO levels one month after treatment.
Conclusions: The nasal FeNO measurement by NObreathⓇ is easy to perform and suitable for monitoring
AR patients in various treatment modalities. Furthermore, it may have potential usefulness as a tool to improve
daily clinical care.
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ABBREVIATIONS
AR, Allergic rhinitis; BA, Bronchial asthma; FeNO, Fractional concentrations of exhaled nitric oxide; HDM,
house dust mites; NO, Nitric oxide; NOS, nitric oxide synthase; ppb, Parts per billion; SAR, Seasonal allergic
rhinitis.
INTRODUCTION
Nitric oxide (NO) is abundantly produced in human
airways by the activation of NO synthase. The frac-
tional concentration of exhaled NO (FeNO) has been
shown to be increased in inflammatory airway dis-
eases, including bronchial asthma (BA),1,2 allergic
rhinitis (AR),3-5 and chronic rhinosinusitis.6,7 There
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has been rapidly increasing interest in monitoring the
FeNO levels. Recently, a new hand-held device with
an electrochemical sensor (NObreathⓇ; Bedfont Sci-
entific Ltd., Rochester, UK) has been developed and
is available in Japan.8,9 These devices have been clini-
cally tested and were shown to provide values in good
agreement with those obtained by the standard
chemiluminescence analyzer.10-12 Allergic rhinitis has
been considered to be associated with increased
FeNO levels, although there is still a divergence of
opinion about whether local inflammation is responsi-
ble for increased levels of FeNO in the disease. Nasal
NO is not routinely measured in daily clinical prac-
tice. One reason may be the heterogeneous results
found in previous studies and the lack of consensus
concerning the most suitable measurement tech-
nique.
In the present study, we measured the FeNO levels
both trans-orally and trans-nasally in a population of
normal subjects, perennial AR patients against house
dust mites (HDM) with or without BA, and patients
with vasomotor rhinitis using a handheld NO ana-
lyzer. The relationship between the FeNO levels and
degree of subjective allergic symptoms was exam-
ined. We also evaluated changes in the FeNO levels
in a group of seasonal allergic rhinitis (SAR) patients
against Japanese cedar during and after the pollen
season, and in a group of perennial AR patients who
underwent laser surgery of the inferior turbinate. We
found that the assessment of nasal FeNO described
here is noninvasive, quickly performed, and may di-
rectly reflect the degree of allergic inflammatory con-
ditions neighboring the surface mucosa of the infe-
rior turbinate.
METHODS
SUBJECTS
One-hundred and sixteen subjects were included in
the cross-sectional study. They are 56 patients with
perennial HDM allergic rhinitis without BA (33 males
and 23 females with a mean age of 32), 18 patients
with perennial HDM allergic rhinitis and BA (11
males and 7 females with a mean age of 31.5), 12 pa-
tients with vasomotor rhinitis (7 males and 5 females
with a mean age of 75.3), and 30 normal volunteers
without nasal symptoms (17 males and 13 females
with a mean age of 34.9). For the follow-up study of
cedar pollinosis, 12 SAR patients against Japanese ce-
dar (6 males and 6 females with a mean age of 33.3)
were enrolled. Measurements were performed dur-
ing the pollen dispersion season (March to April in
2010), when patients demonstrated allergic nasal
symptoms, and 2 to 3 months after the season. For
the follow-up study of laser surgery, 10 patients with
perennial HDM allergic rhinitis who had chronic na-
sal obstruction (6 males and 4 females with a mean
age of 27.7) were enrolled. The surgical procedure
was performed on an outpatient basis and described
in detail elsewhere.13 Briefly, the whole septal surface
of the inferior turbinates was vaporized bilaterally us-
ing a carbon dioxide laser (LESAC CO2-25, LESAC
Co., Funabashi, Japan) equipped with a 45° reflected
handpiece.
Diagnosis of allergic rhinitis was based on clinical
history and a positive serum allergen-specific IgE
score of 2 or greater on the CAP-RAST against HDM
(Dermatophagoides farinae) or Japanese cedar (Cryp-
tomeria japonica). The diagnosis of asthma was con-
firmed by clinical history of respiratory symptoms
based on the Japanese guidelines for the diagnosis
and treatment of allergic diseases 2010. Vasomotor
rhinitis was clinically diagnosed by sporadic or persis-
tent nasal symptoms with the predominant symptom
being rhinorrhea and nasal itching. They were con-
sidered to be non-allergic with normal eosinophil pro-
portion and negative IgE scores against any exam-
ined inhalant allergens. Patients who had been
treated with any allergen-specific immunotherapy
were excluded and did not receive any anti-allergic
medication in the 14 days before the study.
The patients’ subjective symptoms were recorded
at the time of the NO measurement. Symptom scores
were obtained using the following criteria based on a
modified Okuda classification.14 They include the
daily number of sneezes, the frequency of rhinorrhea,
and the degree of nasal congestion. Each symptom
was scored on a scale of 0 to 4 (0 = none, 1 = mild, 2 =
moderate, 3 = severe, and 4 = very severe). The study
protocol was approved by the Institutional Review
Board at the Hiroshima University School of Medi-
cine, and informed consent was obtained from each
subject.
MEASUREMENTS OF NITRIC OXIDE
Measurements of the FeNO level were obtained ac-
cording to the American Thoracic SocietyEuropean
Respiratory Society (ATSERS) guidelines using a
handheld electrochemical analyzer (NObreathⓇ).15
For the oral FeNO measurements, the subjects first
inhaled ambient air to near total lung capacity and
then exhaled for 16 s at a constant flow rate of 50 mL
s through a disposable mouthpiece into the device.8
For the nasal FeNO measurements, the subjects
were advised to blow up their cheeks with mouth
closed and to exhale transnasally with a nose adaptor
attached to the mouthpiece.16 The flow rate and dura-
tion were the same as for the oral FeNO measure-
ment (Fig. 1). Each measurement was performed in
triplicate and the mean value was used for analysis.
After a brief period of training, all patients succeeded
in performing acceptable nasal FeNO measurements.
The detection limit of the device was 1 part per billion
(ppb) and the measurement range was 5 to 256 ppb.
DATA ANALYSIS
Group data were expressed as means ± SD. For mul-
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Fig.　1　A normal subject is exhaling against the disposable (a) mouthpiece and (b) nosepiece connected 
to the handheld analyzer (NObreath®). The nosepiece consists of a nasal olive connected to the mouth-
piece. Different sizes of nasal olives are prepared to adjust nasal valve areas.
(a) oral FeNO
(b) nasal FeNO
tiple comparisons, screening of data for differences
was first carried out using the Kruskal-Wallis test. If
the analysis gave a significant result, further compari-
son was done by the Mann-Whitney U test for
between-group analysis. The comparison between
each visit was assessed with the Wilcoxon rank sum
test. Correlation coefficients were calculated by the
Spearman method. Statistical analysis was carried out
with STATISTICA for Windows (StatSoft Inc., Tulsa,
OK, USA). A p value < 0.05 was considered signifi-
cant.
RESULTS
FeNO LEVELS IN ALLERGIC PATIENTS
Figure 2 shows the values of oral and nasal FeNO in
each group. The mean oral FeNO levels were 9.9 ±
8.0 ppb in normal subjects, 21.1 ± 11.6 ppb in vasomo-
tor rhinitis patients, 17.3 ± 11.8 ppb in HDM allergic
patients without BA [AR(+)BA(-)], and 96.3 ± 33.6
ppb in HDM allergic patients with BA [AR(+)BA(+)].
Compared with the normal group, the patients in the
other three groups showed significantly higher oral
FeNO levels. In addition, the AR(+)BA(+) patients
showed significantly higher oral FeNO levels com-
pared to the patients in the other two groups. The
mean nasal FeNO levels were 48.6 ± 20.0 ppb in nor-
mal subjects, 46 ± 14.9 ppb in vasomotor rhinitis pa-
tients, 76.9 ± 30.2 ppb in AR(+)BA(-) patients, and
102.7 ± 47.0 ppb in AR(+)BA(+) patients. Compared
with the normal group and vasomotor rhinitis group,
both the AR(+)BA(-) and AR(+)BA(+) patients
showed significantly higher nasal FeNO levels. In ad-
dition, the mean nasal FeNO level of the AR(+)BA(+)
group was significantly higher than that of the AR(+)
BA(-) group. Figure 3 shows the correlation between
the nasal symptom scores and oral or nasal FeNO lev-
els in patients of the AR(+)BA(-) and AR(+)BA(+)
groups. We found weak but positive correlations be-
tween the nasal symptom scores and FeNO levels,
with the coefficient being higher for nasal FeNO than
oral FeNO (r = 0.356 vs. r = 0.303).
CHANGES IN FeNO LEVELS AFTER POLLEN
SEASON
The release of pollen from C. japonica was first ob-
served on February 11 in 2010 and pollen dispersion
lasted for about 60 days. The total pollen counts in
the season were 1286 per cm2. As shown in Figure 4,
the mean oral FeNO levels in the SAR patients were
12.8 ± 9.5 ppb during the season and 12 ± 7.9 ppb af-
ter the season, and the difference was not significant.
The mean nasal FeNO levels in the same patients
were 62.1 ± 21.2 ppb during the season and 43.5 ±
17.4 ppb after the season. All the SAR patients
showed a reduction in the nasal FeNO level at
postseason, and the difference was significant. In ad-
dition, there was no significant difference in the mean
nasal FeNO level between the SAR patients during
the season and the HDM patients in the AR(+)BA(-)
group (p = 0.134).
CHANGES IN FeNO LEVELS AFTER LASER
SURGERY
After laser surgery, all the patients reported a better
Takeno S et al.
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Fig.　2　(a) Oral FeNO and (b) nasal FeNO levels in normal subjects, in patients with vasomotor rhinitis, 
HDM allergic patients without BA [AR(+)BA(-)], and HDM allergic patients with BA [AR(+)BA(+)]. *P < .05; 
**P < .01; FeNO, fractional exhaled nitric oxide.
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Fig.　3　Correlation between nasal symptom scores and (a) oral FeNO levels and (b) nasal FeNO levels 
in patients with HDM allergic patients (n = 74).
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quality of life with improvement of nasal symptoms.
The therapeutic effects generally appeared within 2
weeks with formation of scar tissue in the mucosal
layer of the inferior turbinates. As shown in Figure 5,
the mean oral FeNO levels in the patients were 36.7 ±
30.3 ppb before surgery and 35 ± 37 ppb one month
after surgery, and the difference was not significant.
However, the mean nasal FeNO levels in the same
patients were 108.8 ± 42.9 ppb before surgery and
68.2 ± 54.7 ppb after surgery. The difference was sig-
nificant and 9 out of 10 patients showed a reduction in
the nasal FeNO level.
Measurement of Nasal FeNO
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Fig.　4　Changes in the level of (a) oral FeNO and (b) nasal FeNO during the 
pollen season and after the season. **P < .01.
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Fig.　5　Changes in the level of (a) oral FeNO and (b) nasal FeNO before laser 
surgery and one month after surgery. *P < .05.
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DISCUSSION
The measurement of FeNO has become a reliable
and noninvasive marker of inflammation in human
airways, reflecting the growing interest in this
area.1,2,6,8,9,12 In the present study, we measured the
oral and nasal FeNO levels in normal and allergic
subjects of the Japanese population by using the
NObreathⓇ. In this method, both the upper and
lower airway FeNO levels can be easily measured
with the same NO analyzer sequentially in a short pe-
riod of time. We observed good agreement with
those obtained by previously validated instruments.
Two different methods are recommended by the
American Thoracic Society to assess the NO level in
the nasal cavity, i.e., nasal NO and nasal FeNO.3,5,15
Measurement of nasal NO is performed by aspirating
air from the nasal cavity with a target airflow rate
while the velum is closed during breath hold.17 To
measure nasal FeNO, the subject exhales trans-
Takeno S et al.
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nasally with a fixed flow while the mouth is closed.
Nasal FeNO is considered to represent a fraction of
endogenous NO with contaminated air passing
through the nose with a relatively high flow rate.3 Al-
though measurement of nasal FeNO is easier and
suitable for daily clinical use, it should be kept in
mind that the concentrations depend on several fac-
tors. First, no normative data for a very large popula-
tion including Japanese have so far been published.
Second, the nasal NO output in normal subjects are
usually high relative to the lower respiratory tract,
with the contribution of a reservoir of abundant NO
sources in the paranasal sinuses. Evaluation of the na-
sal FeNO measurement using a handheld analyzer
was carried out in previous studies.2,18 During the ex-
halation process, different flow rates may occur as a
result of changes in the airflow physics caused by
inter-individual differences in the anatomical struc-
ture of the nose. However, Djupesland et al. reported
that interpretation of nasal NO levels was relatively
constant and reliable when trans-nasal flow rates re-
mained in a range between 0.25 and 3 Lmin.19 We
also consider that the reproducibility of this measure-
ment technique with NObreathⓇ is acceptable from a
clinical point of view and the intraindividual variability
within each measure is usually minor in a cooperative
and trained subject.20
Allergic rhinitis has been considered to be associ-
ated with increased FeNO levels mainly by the in-
creased expression of inducible nitric oxide synthase
(iNOS).21-25 Several authors have reported increased
nasal NO levels in symptomatic AR patients.4,26-29 In
these patients, an overexpression of iNOS as well as
an increase in nitrites and nitrates, NO-derived me-
tabolites, was observed in sampled specimens,21 the
breath condensate,4 and nasal lavage fluid.30 Khari-
tonov et al. reported that during the pollen season,
the nasal NO levels, but not the FeNO concentra-
tions, increased in SAR patients.26 Conversely, some
studies revealed no significant differences between
rhinitis patients and control subjects.31,32 Palm et al.
reported increased levels of orally exhaled NO in
SAR patients with a larger interindividual spread,
whereas there were no changes in the nasal NO lev-
els.32 In the present study, significant increase in oral
and nasal FeNO levels was observed in both AR(+)
BA(-) and AR(+)BA(+) patients. Allergic diathesis is
generally associated with increased NO production,
although there is a divergence of opinions whether al-
lergic rhinitis alone is responsible for increased ex-
haled NO levels detected from oral breathing. These
seemingly conflicting results on the NO levels in AR
patients may also reflect the difference in the selec-
tion of the patients studied and their disease back-
grounds. Recently, Maniscalco et al. reported a
slightly higher nasal FeNO level in AR patients com-
pared with healthy subjects (59.0 vs. 49.1 ppb). The
results were obtained by using another portable elec-
trochemical analyzer (NIOX MINOⓇ) from a single
nasally exhaled breath maneuver.20 The data are
compatible with the present cross-sectional study. We
also found significant differences in the nasal FeNO
levels between perennial AR patients and normal con-
trols (76.9 vs. 48.6 ppb).
The presence of bronchial asthma in AR patients
was associated with higher nasal FeNO levels (mean
102.7 ppb). This represents a larger production of en-
dogenous NO derived from both the upper and lower
airways in this group because all patients uniformly
revealed oral FeNO levels more than the cut-off level.
It should be noted that nasal FeNO levels are more
variable and susceptible to the lower airway condition
as compared to nasal NO. Further studies including
direct NO measures inside the nasal cavity are re-
quired to assess exact contribution of nasal NO pro-
duction under the high background levels of oral
FeNO in these patients.
We found increased oral FeNO levels in patients
with vasomotor rhinitis as compared with control sub-
jects, whereas there was no change in nasal FeNO
levels. The mechanisms underlying vasomotor rhini-
tis are considered to be different from allergic rhini-
tis. Generally, vasomotor rhinitis arises from an im-
balance of autonomic input into the nasal mucosa and
enhanced parasympathetic responses, which results
in increased plasma excretion and glandular secre-
tion.33,34 Previous reports observed histological dam-
age to the surface epithelium with impaired mucocili-
ary clearance as well as increased NADPH diapho-
rase activity in these patients.35,36 Possible influence
of age should be considered on FeNO measurement
because the mean age of this group is higher than
the other groups. It has been reported that respira-
tory NO does not appear to be age-dependent in nor-
mal adults and in children after the age of 11
years.37,38 Little information has been available to
date on the FeNO levels of vasomotor rhinitis pa-
tients. We suppose that the difference in the FeNO
levels reflects pathological backgrounds characteris-
tic of the disease and FeNO monitoring can be ap-
plied to differentiate vasomotor rhinitis from peren-
nial AR patients.
There is still some inconsistency as for relation be-
tween nasal FeNO levels and the degree of nasal
symptoms in perennial and seasonal AR patients. The
present follow-up study indicates that nasal FeNO can
be used as a good marker to evaluate inflammatory
conditions of the diseased inferior turbinate in desig-
nated AR patients during the pollen season or after la-
ser surgery. An increasing level of nasal FeNO dur-
ing the pollen season and a moderate decrease in the
off-season have been observed in SAR patients.5,39 On
the other hand, Bozek et al. failed to find a positive
correlation with nasal symptom scores and nasal
FeNO in any of the SAR patients during and after the
pollen season.5 One possible explanation for the di-
Measurement of Nasal FeNO
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vergence is that low NO levels can be seen in certain
conditions such as severe nasal blockage, watery na-
sal polyps, and nasal hypersecretion. Also, high back-
ground levels of NO from constitutive sources, such
as paranasal sinuses, may blunt smaller increases in
nasal NO output.40,41
To date there is little information available on
changes in the FeNO levels after turbinate surgery in
AR patients. Laser surgery has become one of the
most popular methods among ENT surgeons to alle-
viate chronic nasal symptoms in perennial AR pa-
tients because of the improved results and simplicity
of the procedure.42 Rational backgrounds regarding
the efficacy of laser surgery are mainly based on the
degenerative process of the surface epithelium and
scar tissue formation, which is preferable for inter-
ruption of allergic reactions.43 In the present study,
we found significant reduction in the nasal FeNO lev-
els after laser surgery, whereas the oral FeNO levels
remained unchanged. The result clearly indicates
that attenuation of local allergic inflammation is re-
sponsible for decreased nasal FeNO in these patients.
In summary, nasal FeNO measurements obtained
by NObreathⓇ, a portable FeNO analyzer, are easy to
use and suitable for monitoring AR patients in various
treatment modalities as well as for basic research
studies. Furthermore, the measurement may have
potential usefulness as an additional tool to improve
daily clinical care for these patients.
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